RIXIT – 200 LB
Powerful Infection Control with Probiotic Gut Protection
RIXIT-200 LB from Citric Labs combines the broad-spectrum antibacterial action of Cefixime 200 mg with the probiotic benefits of Lactic Acid Bacillus 60 Million Spores. This dual-action formulation helps eliminate susceptible bacteria while maintaining intestinal microflora, reducing the risk of antibiotic-associated diarrhea and improving patient comfort. Cefixime is commonly prescribed for bacterial infections affecting the respiratory tract, ENT region, urinary tract, and other susceptible infections, while Lactic Acid Bacillus helps restore healthy gut bacteria.
Composition
- Cefixime 200 mg
- Lactic Acid Bacillus 60 Million Spores Dispersible Tablets
Key Benefits
- Broad-spectrum antibacterial activity against susceptible bacteria
- Helps manage respiratory tract and ENT infections
- Effective in urinary tract bacterial infections
- Probiotic support helps maintain healthy intestinal flora
- Reduces the risk of antibiotic-associated diarrhea
- Dispersible tablet for easier administration
Product Description
RIXIT-200 LB contains Cefixime 200 mg + Lactic Acid Bacillus 60 Million Spores in dispersible tablet form, providing effective treatment for bacterial infections while supporting healthy gut flora. Manufactured by Citric Labs, it is an excellent choice for PCD Pharma Franchise and Third-Party Pharma Manufacturing across India.
Related products
Why Choose Citric Labs for PCD Pharma Franchise?
- High-quality WHO-GMP certified products
- Monopoly-based PCD Pharma Franchise opportunities
- Strong product portfolio including pain management range
- Competitive pricing & high margins
- Reliable supply chain across India
